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Diabetic patients have increased depression rates, diminished quality of life, and higher death 
rates due to depression comorbidity or diabetes complications. Treatment adherence (TA) and the 
maintenance of an adequate and competent self‑care are crucial factors to reach optimal glycaemic 
control and stable quality of life in these patients. In this report, we present the baseline population 
analyses in phase I of the TELE‑DD project, a three‑phased population‑based study in 23 Health 
Centres from the Aragonian Health Service Sector II in Zaragoza, Spain. The objectives of the present 
report are: (1) to determine the point prevalence of T2D and clinical depression comorbidity and 
treatment nonadherence; (2) to test if HbA1c and LDL‑C, as primary DM outcomes, are related to TA 
in this population; and (3) to test if these DM primary outcomes are associated with TA independently 
of shared risk factors for DM and depression, and patients’ health behaviours. A population of 7,271 
patients with type‑2 diabetes and comorbid clinical depression was investigated for inclusion. 
Individuals with confirmed diagnoses and drug treatment for both illnesses (n = 3340) were included 
in the current phase I. A point prevalence of 1.9% was found for the T2D‑depression comorbidity. The 
prevalence of patients nonadherent to treatment for these diseases was 35.4%. Multivariate analyses 
confirmed that lower diabetes duration, increased yearly PCS visits, HbA1c and LDL‑C levels were 
independently related to treatment nonadherence. These findings informed the development of a 
telephonic monitoring platform for treatment of nonadherence for people with diabetes and comorbid 
depression and further trial, cost‑effectiveness, and prognostic studies (phases II and III).
Diabetes Mellitus (DM) is currently a global health threat affecting more than 380 million people, an alarming 
number predicted to reach 590 million in the year  20351. DM is often accompanied by serious short-term conse-
quences, such as hypoglycaemia, hyperglycaemia, and micro- and macrovascular long-term complications that 
substantially increase patient’s disability and mortality  rates2, while being the cause of more renal failure, blind-
ness, cardiovascular disease, and amputation cases than any known  illnesses3. The prevention and treatment of 
these complications, together with DM chronicity, require a complex self-management throughout the patients’ 
life-course, but also health professionals with a strong commitment with the patients’ education and wellbeing 
by promoting medication adherence, a healthy diet, physical exercise, and blood glucose control, for a better 
 prognosis4. If DM is undiagnosed or untreated, it will significantly increase cardiovascular risk and reduce life 
expectancy while increasing the risk of hospital admissions, and health  costs5.
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Daily and chronic issues lead to increased emotional distress in diabetic patients when compared to the gen-
eral population, being clinical depression the most frequent comorbid  disease6–9 and leaving no doubts about 
the bidirectional association between  them10,11. Moreover, the risk of depression relapse increases progressively 
with each new episode, particularly and negatively impacting DM patient’s  prognosis12. Specifically, diabetic 
patients are on a two-fold increased risk for a major depression disorder (MDD) in the general  population13, 
a injurious comorbidity associated with adverse health issues as higher HbA1c levels and reduced optimal 
self-care  behaviours14,15. In subjects with overweight or obesity, lowering body weight by 5–10% is related with 
bettered insulin sensitivity, improved glycaemic control, lower triglycerides, and elevated HDL-C16. Besides, the 
International Atherosclerosis Society and the European Society of  Cardiology17,18 recommend low-LDL levels 
of 100 mg /dl in diabetics without cardiovascular disease (CVD). Besides, an LDL cholesterol goal lower than 
70 mg/dL should be achieved in T2D patients with high cardiovascular burden or risk (CVD or associated risk 
factors), which has been as well related to a higher risk of new or recurrent clinical depression  episodes19. In 
addition, previous studies indicated a significant correlation between hypertension and depression in old adults 
in community-based  studies20 and indicated that a diastolic blood pressure difference of 5 mmHg significantly 
reduces the complications of death from diabetes and cerebral infarcts and the development of microvascular 
 complications21. Physical inactivity, overweight/obesity, daily smoking, and hypertension have recently been 
demonstrated to be shared, and unique risk factors of DM and depressive  disorders22. Diabetes and depression 
comorbidity significantly increase micro- and macrovascular  complications23,24, elevated health care  use25, and 
death  rates26. In fact, individuals diagnosed with DM and comorbid depressive disorder have 2,5 higher odds to 
die in the next eight years than patients with only DM or  depression26.
An adequate treatment adherence (TA) occurs when patients’ behaviour matches regular prescription and 
advice from health professionals, as medication intake, diet self-monitoring, and/or executing lifestyle  changes27. 
In patients with DM, TA involves the optimization of blood glucose levels and maintaining a healthy lifestyle 
and is considered a determinant factor to improve prognosis by reducing disease outcomes, as incident com-
plications, and  death28,29. A meta-analysis of 513 studies across 50 years indicated a mean TA for DM of 67%, 
being the lowest TA of the 17 main diseases analysed and estimated 7.6 million of visits to the physician prob-
ably ending in  nonadherence30, additionally, a median prevalence of 53% was found for unipolar depression 
treatment non-adherence31. Treatment nonadherence results in catastrophic loss in human lives, and also in 
medical care costs, in fact, the American Diabetes Association (ADA) combined and updated the estimation 
for the economic burden of DM for all ages, including direct and indirect cost, reaching $404 billion in  201732. 
Based on prior research, the objectives of the present report are: (1) to determine the point prevalence of T2D 
and clinical depression comorbidity and treatment nonadherence; (2) to test if HbA1c and LDL-C, as primary 
DM outcomes, are related to TA in this population; and (3) to test if these DM primary outcomes are associated 
with TA independently of shared risk factors for DM and depression, and patients’ health behaviours.
Results
Prevalence data for T2D and depression comorbidity and TA (objective 1). The population of 
Zaragoza (Spain) from the Aragonese Health Service (SALUD) Sector II included 382,169 people of which 
7271 (Fig. 1) were identified from the Community Health System-Electronic Medical Records (CHS-EMR) as 
patients diagnosed with T2D and concurrent clinical depression, resulting in a comorbidity crude point preva-
lence of 1.9%. After reviewing the medical records of these patients, those who had unreliable diagnoses for T2D 
or clinical depression or did not receive pharmacological treatment during the previous year for both diseases, 
or suffered severe psychiatric or cognitive illness, were excluded from the study (n = 3670), while halving the 
comorbidity point prevalence to 0.94%. To obtain the point prevalence of nonadherence vs TA, the remaining 
3601 patients were grouped with regard to TA criteria for T2D, clinical depression, or both, by using the Medica-
tion Possession Ratio or MPR, defining TA as MPR ≥ 80% and nonadherence as MPR < 80%. One hundred and 
eighteen patients adherent only to pharmacological treatment of diabetes and 143 to pharmacological treatment 
of clinical depression were additionally excluded to avoid bias when analyzing the association between quality 
of adherence and study primary outcomes and covariates. Finally, 2066 patients (point prevalence = 57.4%) that 
showed TA and those 1274 patients that presented nonadherence or non-TA (point prevalence = 35.4%) to both 
pharmacological treatments were included in the final TELE-DD phase I baseline study (n = 3340) and current 
report analyses.
Patients characteristics. The mean (Standard Deviation, SD) age of the baseline study patients (n = 3340) 
with T2D and comorbid depression, with or without TA for both antidiabetics and antidepressants pharmaco-
logical treatment, was 72.37 (11.95) years (Table 1). From those 3340 patients 69% were women with 90.2% of 
non-smokers, there was an average of 11.9 (8.6). Primary Care Specialist (PCS) consultation visits per year, and 
those for nurse consultation supposed a mean of 9.0 (11.5) visits during the year preceding the baseline assess-
ment. Patients consumed an average of 6.4 (2.9) drugs.
Association of TA with primary DM outcomes (objective 2). Bivariate analyses by TA indicated sta-
tistically significant differences for diabetes duration in years (p = 0.034), mean HbA1c (p < 0.001), and levels 
ADA 2018 standards and cut-offs, p < 0.001), and LDL-C mean values (p = 0.009) and levels (ATP III criteria, 
p = 0.048). Due to the systematic registration of CHS-EMR, and research nurse’s data collection and investigation 
in health centres data, there were no missing values in any variable used in the baseline population analyses.
Hierarchical multivariate analysis of the association of primary DM outcomes with TA (objec‑
tive 3). In Table 2 a multivariate approach was used where all study variables were continuous but sex and 
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smoking status. Unadjusted LR results confirmed significant findings from prior bivariate analyses displayed in 
Table 1. After further adjustment for shared T2D-depression risk factors and patients health behaviours similar 
findings were obtained, as shown in model 3 in Table 2. Furthermore, an inverse linear association of T2D dura-
tion in years and nonadherence was found (p = 0.001), showing that patients with a lesser T2D disease duration 
since diagnosis had an increased risk for nonadherence. On the other hand, final model 3 confirmed a direct 
linear relationship between the increased number of yearly PCS visits (p = 0.021) and in HbA1c (p < 0.001) and 
LDL-C mean values (p = 0.012) between patients with TA when compared with those patients with treatment 
nonadherence for both illnesses, indicating that increased values in those variables were significantly associated 
with nonadherence. Of note, Table 2 shows that T2D patients with comorbid depression had a 42% higher odds 
per point increase in HbA1c for nonadherence to both T2D and depression treatments when compared to those 
with TA. Table 3 shows the main findings of a second multivariate approach, including the categorization of pri-
 
Excluded from baseline study 
n = 261 
Data from SALUD Sector II CHS-EMR: 
Patients with ICPC-2 diagnoses for T2D and depression  
n = 7,271 
n = 3,601 
Medical records review: Treatment Adherence (TA) calculated under 
Medication Possession Ratio (PPR) criteria: TA: MPR • 80% 
Nonadherence: MPR < 80% 
TA for T2D and 
depression 
n = 2,066 
Nonadherence for both 
T2D and depression 
n = 1,274 
TA only for 
depression 
n = 143 
TA only for
T2D 
n = 118 
Included in population-based baseline study 
and current report analyses 
n = 3,340 
Exclusion criteria applied on medical records review: 
 
- Patients with unreliable diagnoses for T2D or clinical 
depression during the previous year 
 
- Absence of pharmacological treatment during the previous 
year for both diseases 
 
- Presence of severe psychiatric or cognitive illness diagnoses 
 
3,670 Excluded  
Population registered in SALUD Sector II (Zaragoza, Spain) 
N = 382,169 
Figure 1.  TELE-DD project flowchart.
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mary outcomes according to well-known standards, indicating the same linear results on TA for T2D duration 
and physician appointments.
HbA1c independent association with TA. A direct linear association was found (Table 3) for Hb1Ac 
when using the ADA 2018 standards and cut-offs for diagnosis and outcomes and showing that the population 
with prediabetes are close to reaching a two-fold increased risk of nonadherence. When patients HbA1c is situ-
ated in the first level of a T2D diagnose (6.5–6.99%; or 48–52 mmol/mol), the risk for nonadherence lowers to a 
50% odds; when HbA1c increases above 7% or 53 mmol/mol that increased risk augments proportionally, from 
a 127% odds (OR = 2.27; CI = 1.53–3.37) on the 7–7.99% range to an 860% odds (OR = 9.6; CI = 5.42–17.01) on 
the group of patients with HbA1c levels above 10% (or 86 mmol/mol).
LDL‑C independent association with TA. Conversely, LDL-C levels according to ATP III cut-off Crite-
ria show no significant association to TA except for the category ranging from 130 to 159.99 mg/dL, which shows 
a 1.4-fold increased risk of nonadherence for both T2D and depression pharmacological treatment. A forest 
plot in Fig. 2 displays OR and CI of the statistically significant variables of the fully adjusted model 3 shown in 
Table 3.
Table 1.  Baseline TELE-DD population characteristics of patients with type-2 diabetes and comorbid clinical 
depression by treatment adherence. † Total N = 3340 for all variables.
Variables† TA Non-TA p (95%)
Age, years (Mean, SD) 72.57 (11.80) 72.04 (12.19) .210
Sex (n, %)
Female 1446 (70.0%) 859 (67.4%) .119
Male 620 (30.0%) 415 (32.6%)
Diabetes duration, years (Mean, SD) 8.80 (5,63) 8.38 (5.62) .034
Depression duration, years (Mean, SD) 8.31 (5.20) 7.96 (4.99) .058
Nurse appointments, yearly Mean, SD) 8.98 (11.11) 9.00 (12.18) .959
PCS appointments, yearly (Mean, SD) 11.66 (8.39) 12.14 (8.76) .116
Drug intake (No.) (Mean, SD) 6.34 (2.88) 6.36 (2.96) .893
Smoking status, current
No 1873 (90.7) 1.141 (89.6) .299
Yes 193 (9.3) 133 (10.4)
BMI (Mean, SD) 30.70 (5.45) 30.38 (5.28) .094
BMI, WHO Criteria (n, %)
Normal 259 (12.5) 170 (13.3) .796
Pre-obesity 781 (37.8) 486 (38.1)
Obesity class I 607 (29.4) 375 (29.4)
Obesity class II 289 (14.0) 175 (13.7)
Obesity class III 130 (6.3) 68 (5.3)
Systolic blood pressure (Mean, SD) 134.95 (16,68) 134.76 (16.99) .756
Diastolic blood pressure (Mean, SD) 76.11 (10.05) 75.83 (10.02) .436
HbA1c (Mean, SD) 6.99 (1.10) 7.51 (1.41) .000
HbA1c levels (n, %, ADA 2018 criteria)
 < 5.7 131 (6.3) 37 (2.9) .000
5.7–5.99 130 (6.3) 71 (5.6)
6–6.49 474 (22.9) 238 (18.7)
6.5–6.99 445 (21.5) 195 (15.3)
7–7.99 506 (24.5) 305 (23.9)
8–8.99 247 (12) 215 (16.9)
9–9.99 104 (5) 139 (10.9)
 > 10 29 (1.4) 74 (5.8)
LDL-C (Mean, SD) 105.97 (33.27) 109.09 (33.54) .009
LDL-C levels (n, %, ATP III criteria)
 < 100 989 (47.9) 559 (43.9) .048
100–129.99 624 (30.2) 380 (29.8)
130–159.99 315 (15.2) 240 (18.8)
160–189.99 105 (5.1) 71 (5.6)
 > 190 33 (1.6) 24 (1.9)
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Discussion
The baseline results show that the TELE-DD diabetic population with comorbid clinical depression is gener-
ally old and predominantly female, coincident with previous studies that reported similar characteristics and 
prevalence data in a similar  setting8,10. The baseline assessment showed a 57.4% of patients with TA to T2D 
and depression, our data being comparable to those previously  reported33,34. Our findings show that 35.4% of 
patients do not use their medication correctly, a large number considering the impact on their QOL, wellbeing 
and further prognosis, while coincident with  DiMatteo30 meta-analysis finding from 513 studies across 50 years, 
that indicated a mean nonadherence for DM of 34%. Also, we found that lesser diabetes duration, increased 
primary care specialist visits, and HbA1c levels are key factors associated with nonadherence to treatment in 
this population with T2D and comorbid depression. In this sense, significant results have been found for the 
HbA1c as a continuous variable, been consistent with prior  studies35–37. In addition, by categorizing the HbA1c 
values according to the ADA standards, we found that a higher risk of nonadherence is related to higher val-
ues of HbA1c. In fact, and regardless of the convenience on using continuous variables in a first multivariate 
approach, categorization is necessary to assess the risk of nonadherence with respect to well-known standards on 
HbA1c and LDL-C, and also for further comparisons with other studies while facilitating the translation of our 
findings to PC services. We found that patients in the prediabetes state have an increased risk of failing in both 
treatments between 78 and 93%, being a higher risk than those with HbA1c levels of 6.5–7%. Moreover, the risk 
of nonadherence has been related in our population with lesser diabetes duration and increased HbA1c values, 
reaching levels of concern that indicate the urgent convenience of implementing intervention and prevention 
programs aimed to TA increase in patients with high HbA1c levels and those with persistent or recurrent clinical 
depression. Findings of PCS and nurse consultation visits had similar average scores but, according to Pouwer 
et al.38, the number of consultations has a direct impact on TA and, surprisingly, our data indicate that a higher 
number of visits results in a worse adherence, nevertheless, patients with worse TA have worsened prognosis, as 
increased risk of depression relapse and DM complications, requiring further consultations than those patients 
with uncontrolled  TA39, although this association may also be due to reverse causality bias. The mean number of 
drug intake was 6.4, similar to the data reported by Patel et al.40, as complexity in treatment has been reported as 
the main cause of nonadherence, and a consequence of the increased burden of multimorbidity, mainly due to 
Table 2.  Risk estimation for treatment nonadherence for primary DM outcomes and study covariates through 
hierarchical multivariate logistic regression models on diabetic patients with comorbid depression (N = 3340). 
Model 1 = Adjusted by age, gender, and primary DM outcomes (HbA1c and LDL Cholesterol). Model 
2 = Model 1 + T2D duration (years), depression duration (years), nurse and PCS visits, and smoking status. 
Model 3 = Model 2 + # drug intake, BMI, systolic blood pressure, diastolic blood pressure. *p < .05; **p < .01.
Study variables Categories
Unadjusted Model 1 Model 2 Model 3
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age Increased score 1.00 0.99 1.01 1.00 0.99 1.01 1.00 0.99 1.01 1.00 0.99 1.01
Sex
Female 1.00 1.00 1.00 1.00
Male 1.13 0.97 1.31 1.16 0.98 1.36 1.12 0.95 1.33 1.12 0.94 1.32
Diabetes duration, years
Ref 1.00 1.00 1.00
Increased score 0.98* 0.97 0.99 0.98** 0.97 0.99 0.98** 0.96 0.99
Depression duration, years
Ref 1.00 1.00 1.00
Increased score 0.98 0.97 1.01 0.99 0.98 1.01 0.99 0.98 1.01
Nurse visits
Ref 1.00 1.00 1.00
Increased score 1.00 0.99 1.01 1.00 0.99 1.01 1.00 0.99 1.00
PCS visits
Ref 1.00 1.00 1.00
Increased score 1.01 1.00 1.02 1.01* 1.00 1.02 1.01* 1.00 1.02
Drug intake (#)
Ref 1.00 1.00
Increased score 1.00 0.98 1.03 0.99 0.96 1.02
Smoking Status
Ref 1.00 1.00 1.00
Current smoker 1.13 0.90 1.43 1.16 0.90 1.49 1.15 0.90 1.48
BMI
Ref 1.00 1.00
Increased score 0.99 0.98 1.01 0.99 0.97 1.00
Systolic Blood pressure
Ref 1.00 1.00
Increased score 1.00 0.99 1.01 1.00 0.99 1.01
Blood Diastolic pressure
Ref 1.00 1.00
Increased score 1.00 0.99 1.01 1.00 0.98 1.01
HbA1c
Ref 1.00 1.00 1.00 1.00
Increased score 1.39** 1.31 1.48 1.39** 1.32 1.48 1.42** 1.34 1.50 1.42** 1.34 1.51
LDL Cholesterol
Ref 1.00 1.00 1.00 1.00
Increased score 1.01** 1.01 1.01 1.01** 1.01 1.01 1.01** 1.01 1.01 1.01* 1.01 1.01
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Table 3.  Risk estimation for treatment nonadherence of primary DM outcomes by cut-off standards through 
hierarchical multivariate logistic regression models on diabetic patients with comorbid depression (N = 3340). 
Model 1 = Adjusted by age, gender, and primary DM outcomes: HbA1c, ADA criteria; and LDL Cholesterol, 
ATP III criteria. Model 2 = Model 1 + T2D duration (years), depression duration (years), nurse and PCS visits, 
and smoking status. Model 3 = Model 2 + : # drug intake, BMI, systolic blood pressure, diastolic blood pressure. 
Only variables with significant results are displayed in this table. *p < .05; **p < .01.
Study variables Categories
Unadjusted Model 1 Model 2 Model 3
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Diabetes duration, years
Ref 1.00 1.00 1.00
Increased score 0.98* 0.97 0.99 0.98** 0.97 0.99 0.98** 0.97 0.99
PCS visits
Ref 1.00 1.00 1.00
Increased score 1.01 1.00 1.02 1.01* 1.00 1.02 1.01* 1.00 1.02
HbA1c, ADA 2018 standards and cut-offs for diag-
nosis and outcomes
 < 5.7 (Ref., Normal) 1.00 1.00 1.00 1.00
5.7–5.99 (Prediabetes) 1.93** 1.21 3.08 1.90** 1.19 3.03 1.89** 1.19 3.02 1.91** 1.20 3.06
6–6.49 (Prediabetes) 1.78** 1.20 2.64 1.76** 1.18 2.62 1.75** 1.18 2.61 1.78** 1.20 2.65
6.5–6.99 (Diabetes) 1.55* 1.04 2.32 1.54* 1.03 2.30 1.56* 1.04 2.33 1.58* 1.06 2.37
7—7.99 (Diabetes) 2.13** 1.44 3.16 2.14** 1.44 3.16 2.22** 1.50 3.29 2.27** 1.53 3.37
8–8.99 (Diabetes) 3.08** 2.05 4.64 3.08** 2.04 4.64 3.20** 2.12 4.83 3.27** 2.16 4.94
9–9.99 (Diabetes) 4.73** 3.03 7.38 4.81** 3.08 7.51 5.03** 3.21 7.87 5.17** 3.30 8.11
 > 10 (Diabetes) 9.03** 5.14 15.87 8.98** 5.08 15.85 9.39** 5.31 16.62 9.60** 5.42 17.01
LDL Cholesterol, ATP III Criteria
 < 100 (Ref.) 1.00 1.00 1.00 1.00
100–129.99 1.08 0.91 1.27 1.12 0.95 1.33 1.13 0.95 1.34 1.12 0.95 1.33
130–159.99 1.35* 1.11 1.64 1.42** 1.16 1.74 1.40** 1.14 1.72 1.38** 1.12 1.70
160–189.99 1.20 0.87 1.65 1.15 0.83 1.60 1.15 0.83 1.61 1.16 0.83 1.62
 > 190 1.29 0.75 2.20 1.11 0.63 1.95 1.10 0.62 1.93 1.11 0.63 1.96
Diabetes duration, years
Primary Care Specialist visits
HbA1c 5.7 - 5.99 (Prediabetes)
HbA1c 6 - 6.49 (Prediabetes)
HbA1c 6.5 - 6.99 (Diabetes)
HbA1c 7 - 7.99 (Diabetes)
HbA1c 8 - 8.99 (Diabetes)
HbA1c 9 - 9.99 (Diabetes)
HbA1c >10 (Diabetes)
LDL Cholesterol (100 - 129.99)
LDL Cholesterol (130 - 159.99)
LDL Cholesterol (160 -189.99)
LDL Cholesterol (>190)
0 1 2 3 4 5 6 7 8 9 10
Odds Ratios for Treatment Nonadherence 
Figure 2.  Forest plot for primary outcomes and significant covariates on treatment nonadherence in type 2 
diabetes patients with comorbid depression.
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the high number of drugs prescribed and the difficulty of handling fractionated  doses41. Limitations: The CHS-
EMR does not include data from private healthcare services, that could have been used by an estimated 16% of 
the study population. Specific measures for depression and DM distress are not yet systematically assessed and 
recorded in the CHS-EMR for DM patients, so they could not be included in current baseline analyses as covari-
ates. Besides, our secondary data study design is cross-sectional, and all variables data (including exposures and 
outcomes) was obtained simultaneously, hence the direction of the association between variables cannot be accu-
rately identified, in addition we had no access to the precise number of patients matching each exclusion criteria.
Our baseline population data show an average patient profile of an old-aged woman with nonadherence, 
pre-obesity or stage-I obesity, moderately high levels of LDL-Cholesterol and HbA1C levels, polypharmacy 
treatment, and frequent PCS visits. Bearing in mind that most of them live in poor districts with a dependency 
rate of 52%, and 12% of these are elders living alone, sets the urgent need of investigating and targeting this 
population social determinants of  health42. In addition, the overly complex and stressful daily tasks of chronic 
DM self-management, and the emotional distress of elderly patients with comorbid clinical depression, also set 
the urgent need of health professionals personal contact, monitoring and emotional support for a higher disease 
self-management and TA in reducing adverse outcomes while increasing prognosis and wellbeing in diabetic 
patients with comorbid  depression43. Besides, the present pandemic context due to the SARS-CoV-2 coronavirus 
set an immediate need for tele-health monitoring. For these reasons, the current phase I results have informed 
the development of a telephonic monitoring platform for treatment of nonadherence for people with diabetes 
and comorbid depression to be implemented in SALUD Sector II, to be tested in following phases II and III. 
The aim of the next study on phase II, a pragmatic RCT nested into TELE-DD population-based study, will be 
to test the efficacy of a proactive motivational telephonic monthly intervention, centred on a psychological and 
educational individualized monitoring protocol, to increase TA and disease prognosis on individuals with T2D 
and concurrent depression while reducing health costs, in a random stratified sample of patients from the cur-
rent report phase I population. Those phase II findings, together with future 5- to 10-years follow-up prognostic 
study results (phase III), will allow further comparisons between RCT findings and follow-up data, to determine 
the potential reduction on incident complications and death  rates24, the intervention costs-effectiveness, and 
will enable the TELE-DD intervention protocol to be translated to habitual primary care, specialized clinical 
practice, and public health prevention programs.
Methods
Design, setting, and baseline population. The baseline assessment of a population-based secondary 
data study was performed in TELE-DD Study phase I (Fig. 1), including the full population of adult (21 + years) 
patients diagnosed with T2D and concurrent clinical depression belonging to the 23 Health Centres from the 
Aragonese Health Service (SALUD) Sector II, in the city and province of Zaragoza, Aragon (Spain). These 23 
Health Centres are distributed throughout the city and several neighbour districts and towns and will guarantee 
a both diverse and representative population of research patients. Sector II includes a total population of 382,169 
inhabitants, containing most of poor (low-income) districts from the city of Zaragoza, including 33% of people 
and 12% of retired elders (> 65 yr) living alone and a dependency ratio of 52% relating the number of children 
under age 14 and elders over 65 to the working-age population.
Patient’s eligibility and diagnostic criteria. Eligible for inclusion in the TELE-DD baseline study were 
all patients with concurrent T2D and clinical depression diagnoses recorded in the SALUD health electronic 
system to December 31st, 2015, according to the CHS-EMR registration system that uses the OMI-Primary 
Care (OMI-PC) computerized platform. Diagnoses correspond with the International Classification of Primary 
Care-2nd Edition (ICPC-2) codes T90 (type 2 diabetes) and P76 (clinical depression) and were registered and 
confirmed by the patient’s PCS; the ICPC-2 system has the highest specificity due to its conversion structure with 
the International Classification of Diseases (ICD-10).
Exclusion criteria. Unreliable ICPC-2 diagnoses for T2D or depression or absence of pharmacological 
treatment for both diseases during the previous year. Patients with severe psychiatric or cognitive illness diag-
noses were also excluded.
Data acquisition and management. All data for primary outcomes and covariates were obtained from 
the CHS-EMR, that systematically registers every patient data from all health services, including biochemical, 
PC, nursing, medical and other specialist services.
Treatment adherence. Standard measurements of TA were defined through the medication possession 
ratio (MPR), corresponding to the number of drug units prescribed divided by the number of drug units sched-
uled for a specific time  period44. This formula accounts for the rate of real-time/ scheduled time being treated: 
100 × ∑ (days supplied)/365 (one year). The time in days being treated was predicted as the number of drug units 
prescribed during the observation year, presuming that drug dosage corresponds to one daily drug treatment 
during the year before the baseline assessment. When TA was calculated, a binary variable was generated as TA 
presence/absence under standard criteria of TA = MPR ≥ 80% and nonadherence = MPR < 80%38,45,46.
Primary DM outcomes: glycosylated haemoglobin. HbA1c levels and cut points were classified 
according to the ADA standards of medical care on the classification and diagnosis of diabetes, as follows: 
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Normal HbA1c < 5.7 (38 mmol/mol or lower); Prediabetes HbA1c = 5.7–6.49 (39–47 mmol/mol); and Diabetes 
HbA1c ≥ 6.5–6.99 (48 mmol/mol or higher)47.
Low‑density lipoprotein cholesterol. LDL-C values were annotated following the indications and num-
bers of reference from the National Cholesterol Education Program Adult Treatment Panel  III17,18: < 100 mg/
dl optimal, 100–129 mg/dl regular level, 130–159 mg/dl regular-elevated, 160–189 mg/dl elevated, > 190 mg/dl 
high risk.
Covariates: Health behaviours and shared risk factors of T2D and depression. We collected data 
at the baseline assessment from the year of T2D diagnosis and the year of first depression diagnosis. Patient 
health behaviour indicators were also gathered, including the number of yearly visits to PCS and nursing profes-
sionals before the baseline assessment, current smoking status, detailed pharmacological treatment for diabetes 
and depression, and the number of prescribed medications. The body mass index (BMI) was also calculated 
as the rate of weight in kilograms/height in meters  squared16; Blood pressure was registered according to the 
National Institute for Health and Clinical Excellence  guidelines48.
Statistical analyses. In the current report, we performed standard calculations of point prevalence for a 
representative sample, as the number of people in the sample with T2D and clinical depression comorbidity, or 
these diseases TA or nonadherence, divided by the total number of people in the population of SALUD Sector 
II (objective 1). Secondly, a bivariate analysis of the study primary outcomes and covariates with TA was carried 
out through chi-square test for categorical variables and Student’s t-test for continuous variables, with Levene’s 
test to test homogeneity of variance; in the case of a non-normal distribution, Mann–Whitney U and Kruskal–
Wallis techniques were utilized (objective 2). Further analyses for risk estimation were first completed with 
bivariate binary logistic regression (LR) models. Finally, a hierarchical multivariate LR was performed stratify-
ing models by hypothesis-guided covariate groups; in those models, all variables were included as continuous 
when possible to avoid data loss and/or the confounding effect due to variables categorization (objective 3). 
We included overweight/obesity (trough stratified IMC), daily smoking, and hypertension (high blood pres-
sure) in the equation because they have recently been identified as shared and unique risk factors of both DM 
and depressive disorders, and we wanted to test their potential confounding effect in the association between 
primary outcomes (HbA1c and LDL-C) and nonadherence in patients with T2D and depression comorbidity. 
Diabetes and depression duration were selected for the same reason (potential confounding effect). Further-
more, we selected # drug intake, and the number of outpatient visits to nursing or primary care specialist (PCS) 
as covariates for two different hypothesis-guided reasons, firstly because they are health-state indicators and 
behaviours that may mediate the association between primary outcomes and treatment adherence, and secondly, 
we included these measures of health resources utilization as economic burden proxies. Statistical calculations 
were completed with IBM SPSS 22.0, licensed by the University of Zaragoza.
Ethical concerns and considerations. The study design and procedures were previously evaluated and 
furtherly approved by SALUD Sector II Health Research Commission, the Secretary of the Quality of Care 
and Assistance Unit of SALUD and authorized by the Clinical Ethical Research Committee of Aragon, Spain 
(CEICA, Exp. CP-CI-PI17-0167) and was designed according to ethical standards as indicated in the Declara-
tion of Helsinki and its subsequent amendments. Patient safety and data confidentiality has been fully guaran-
teed, maintaining at all times the anonymity of the patients, coding the cases without names or any identifica-
tion that could link them to the population. This secondary study report population database was issued from 
SALUD public health services after the study design and procedures fulfilled formal and legal procedures and 
were approved by the above-mentioned Commissions and Ethical Committee. In this regard, informed consent 
was not required following recent bioethics recommendations since this report study design and research is 
solely based in secondary data, being clearly benign and has been proven to have no negative effects on clinical 
or other outcomes or values that matter to patients, proceeding without consent but with "public notification to 
the patient community in the healthcare services”49,50.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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